PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8976197-6 1996 Treatment of TGF-beta 1 -/- mice with rapamycin abrogated the characteristic inflammatory wasting syndrome and prolonged survival indefinitely, but did not result in population of the epidermis with LC. Sirolimus 38-47 transforming growth factor, beta 1 Mus musculus 13-23 33559185-3 2021 In this study, we examined whether intravitreal injection of TGF-beta1 into the mouse eye elicits senescence-like morphological alterations in the RPE and if this can be prevented by suppressing mammalian target of rapamycin complex 1 (mTORC1) or NADPH oxidase (NOX) signaling. Sirolimus 215-224 transforming growth factor, beta 1 Mus musculus 61-70 31358596-12 2019 Mycophenolate and rapamycin also down-regulated mTOR and extracellular signal-regulated kinase (ERK) phosphorylation and inhibited fibrotic responses in mesangial cells that were induced by anti-dsDNA antibodies or TGF-beta1. Sirolimus 18-27 transforming growth factor, beta 1 Mus musculus 215-224 30692064-0 2019 [Rapamycin alleviates inflammation by up-regulating TGF-beta/Smad signaling in a mouse model of autoimmune encephalomyelitis]. Sirolimus 1-10 transforming growth factor, beta 1 Mus musculus 52-60 30692064-8 2019 High-dose rapamycin obviously inhibited the production of IL-12, IFN-gamma, IL-17 and IL-23 and induced the anti-inflammatory cytokines IL-10 and TGF-beta. Sirolimus 10-19 transforming growth factor, beta 1 Mus musculus 146-154 30692064-10 2019 In the in vitro experiment, combined treatments of the lymphocytes isolated from the mice with rapamycin and TGF-beta induced a significant increase in the number of Treg cells (13.66+-1.89) compared with the treatment with rapamycin (6.23+-0.80) or TGF-beta (4.87+-0.85) alone. Sirolimus 95-104 transforming growth factor, beta 1 Mus musculus 250-258 30107854-9 2018 Activation of mTORC1, TGF-beta and NF-kappaB signaling pathways was determined in irradiated renal tissues, which were inhibited by rapamycin treatment. Sirolimus 132-141 transforming growth factor, beta 1 Mus musculus 22-30 28333137-7 2017 In addition, the expression of pro-inflammatory cytokines IL-1beta and IFN-gamma mRNA was downregulated while the expression of TGF-beta1 and Foxp3 mRNA was upregulated in kidney tissue after transferring rapamycin-treated MDSCs. Sirolimus 205-214 transforming growth factor, beta 1 Mus musculus 128-137 28333137-8 2017 Adoptive transfer of rapamycin-treated MDSCs also downregulated the serum levels of IL-1beta, IL-6 and IFN-gamma and upregulated the serum levels of TGF-beta1 compared with the IR group and PBS-treated MDSC group. Sirolimus 21-30 transforming growth factor, beta 1 Mus musculus 149-158 26481278-13 2016 Rapamycin treatment markedly induced regulatory B lymphocytes (B220(+)IgM(+)IgG(-)IL-10(+)TGF-beta1(+)) cells when compared with dimethyl sulfoxide controls. Sirolimus 0-9 transforming growth factor, beta 1 Mus musculus 90-99 26782505-0 2015 Influence of sirolimus-induced TGF-beta secretion on mouse Treg cell proliferation. Sirolimus 13-22 transforming growth factor, beta 1 Mus musculus 31-39 26782505-6 2015 Sirolimus-promoted differentiation and proliferation was examined using a TGF-beta neutralizing antibody. Sirolimus 0-9 transforming growth factor, beta 1 Mus musculus 74-82 26782505-7 2015 Sirolimus-treated CD4+ T cell TGF-beta secretion increased 2.5X over control levels (P < 0.01), but that of the cyclosporine group decreased marginally (P > 0.05). Sirolimus 0-9 transforming growth factor, beta 1 Mus musculus 30-38 26782505-11 2015 Sirolimus might promote CD4+ CD25+ FoxP3+ regulatory T cell proliferation by inducing TGF-beta secretion in vivo. Sirolimus 0-9 transforming growth factor, beta 1 Mus musculus 86-94 25534817-6 2015 Collectively, this study identifies a previously unrecognized role of the FBN1/TGF-beta/IL4Ralpha/mTOR cascade in BMMSC lineage selection and provides experimental evidence that rapamycin treatment may provide an anabolic therapy for osteopenia in Fbn1(+/-) mice. Sirolimus 178-187 transforming growth factor, beta 1 Mus musculus 79-87 25559956-17 2015 CONCLUSIONS: This study demonstrates that RAPA treatment effectively suppresses PQ-induced alveolar collapse and collagen deposition in lung tissues through reducing the expression of TGF-beta1 and alpha-SMA. Sirolimus 42-46 transforming growth factor, beta 1 Mus musculus 184-193 24851949-0 2014 Rapamycin attenuates pulmonary allergic vasculitis in murine model by reducing TGF-beta production in the lung. Sirolimus 0-9 transforming growth factor, beta 1 Mus musculus 79-87 24851949-13 2014 CONCLUSIONS: Rapamycin suppressed pulmonary vascular remodeling in a murine model of allergic vasculitis with eosinophil infiltration through reducing eosinophil infiltration and TGF-beta production in the lung and inhibition against biological action of TGF-beta. Sirolimus 13-22 transforming growth factor, beta 1 Mus musculus 179-187 24851949-13 2014 CONCLUSIONS: Rapamycin suppressed pulmonary vascular remodeling in a murine model of allergic vasculitis with eosinophil infiltration through reducing eosinophil infiltration and TGF-beta production in the lung and inhibition against biological action of TGF-beta. Sirolimus 13-22 transforming growth factor, beta 1 Mus musculus 255-263 24742865-9 2014 Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues. Sirolimus 15-24 transforming growth factor, beta 1 Mus musculus 79-87 24515103-7 2014 Western blot and morphological analyses indicated that TGF-beta signaling manipulated primordial follicle growth through tuberous sclerosis complex/mTORC1 signaling in oocytes, and the mTORC1-specific inhibitor rapamycin could partially reverse the stimulated effect of SD208 on the oocyte growth and decreased the numbers of growing follicles. Sirolimus 211-220 transforming growth factor, beta 1 Mus musculus 55-63 24049142-8 2013 Reactive oxygen species (ROS) increased by 32% after TGF-beta1 exposure for 48 h. TGF-beta activated the mammalian target of rapamycin (mTOR) pathway, and rapamycin reduced the TGF-beta1-stimulated increases in OCR, ECAR, ATP generation, cellular metabolic activity, and protein generation. Sirolimus 125-134 transforming growth factor, beta 1 Mus musculus 53-62 23716625-10 2013 Corneal TGF-beta1 levels were lower in the rapamycin-treated group than in the control group at 4 weeks after chemical burn injury (P < 0.05). Sirolimus 43-52 transforming growth factor, beta 1 Mus musculus 8-17 23716625-13 2013 Rapamycin protected the cornea from chemical damage via reduction of IL-6 and TGF-beta1 expression. Sirolimus 0-9 transforming growth factor, beta 1 Mus musculus 78-87 22470459-7 2012 In vitro study confirmed that rapamycin significantly inhibited the fibrogenic activation of cultured fibroblasts (NIH3T3 cells), which was induced by the stimulation of TGF-beta(1). Sirolimus 30-39 transforming growth factor, beta 1 Mus musculus 170-181 19956083-8 2010 Hence, we conclude that TGF-beta1 causes peritoneal injury through Smad-dependent and Smad-independent pathways; the latter involves redundant mechanisms inhibited by rapamycin, suggesting that suppression of both pathways may be necessary to abrogate mesothelial transition. Sirolimus 167-176 transforming growth factor, beta 1 Mus musculus 24-33 12631072-11 2003 Immunostaining of lung tissues for von Willebrand factor was minimal and circulating levels of VEGF-A and TGF-beta1 were lower in the rapamycin-treated mice compared to untreated or cyclosporine-treated mice. Sirolimus 134-143 transforming growth factor, beta 1 Mus musculus 106-115 12202955-3 2002 Furthermore, since the rapamycin receptor protein binds transforming growth factor beta (TGF-beta) receptors, and TGF-beta enhances osteoclastogenesis induced by RANKL, we also examined potential synergistic effects of rapamycin and TGF-beta1. Sirolimus 23-32 transforming growth factor, beta 1 Mus musculus 89-97 12202955-9 2002 Rapamycin also increased osteoclastic resorption activity by 6.5-fold compared with control, and this was enhanced further by the addition of TGF-beta by 3-fold, compared with rapamycin alone. Sirolimus 0-9 transforming growth factor, beta 1 Mus musculus 142-150 12202955-9 2002 Rapamycin also increased osteoclastic resorption activity by 6.5-fold compared with control, and this was enhanced further by the addition of TGF-beta by 3-fold, compared with rapamycin alone. Sirolimus 176-185 transforming growth factor, beta 1 Mus musculus 142-150 11935154-9 2002 Islet grafts from sirolimus plus tacrolimus-treated mice expressed significantly decreased mRNA contents of Th1-type cytokines (IFN- gamma and IL-2) and the highest ratio of TGF- beta1/IFN- gamma mRNA. Sirolimus 18-27 transforming growth factor, beta 1 Mus musculus 174-177 11935154-10 2002 CONCLUSION/INTERPRETATION: These findings suggest that combination therapy with sirolimus and tacrolimus prevent autoimmune beta-cell destruction by upregulating expression of the immunoregulatory cytokine, TGF- beta1 and reducing Th1 cytokines (IFN- gamma and IL-2) expressed in the islets. Sirolimus 80-89 transforming growth factor, beta 1 Mus musculus 207-217 11045651-1 2000 BACKGROUND: Under certain conditions rapamycin and transforming growth factor- (TGF) beta have similar immunoregulatory effects, suggesting a potential functional link between rapamycin and TGF-beta. Sirolimus 37-46 transforming growth factor, beta 1 Mus musculus 190-198 10886809-4 2000 To preclude interference from maternally transferred transforming growth factor-beta1, cutaneous wounds were also made on the backs of 30-day-old transforming growth factor-beta1 null and littermate control mice treated with rapamycin, which extends their lifetime and suppresses the inflammatory response characteristic of the transforming growth factor-beta1 null mice. Sirolimus 225-234 transforming growth factor, beta 1 Mus musculus 146-178 10886809-4 2000 To preclude interference from maternally transferred transforming growth factor-beta1, cutaneous wounds were also made on the backs of 30-day-old transforming growth factor-beta1 null and littermate control mice treated with rapamycin, which extends their lifetime and suppresses the inflammatory response characteristic of the transforming growth factor-beta1 null mice. Sirolimus 225-234 transforming growth factor, beta 1 Mus musculus 146-178